Drug intelligence / Profile preview

Naviron

Development stage: Unknown
Lead developer: Navil Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**Naviron** is a Navil Laboratories oral haematinic fixed-dose product containing **ferrous ascorbate** and **folic acid**. It is used to replenish iron and folate, support haemoglobin synthesis and red-blood-cell production, and treat or prevent iron- and folate-deficiency anaemia. Naviron is marketed in oral tablet and liquid formulations; Navil's closely named Naviron XT suspension lists ferrous ascorbate 30 mg plus folic acid 500 mcg. ([navillab.in](https://navillab.in/product/naviron-xt-suspension/))

Brand names: Naviron

Beyond the preview

Go deeper on Naviron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naviron.

Explore the full profile